(Photo Courtesy: www.widener.edu)
AstraZeneca which outsourced its IT requirement to IBM in 2001, is now ending its relationship with the IT major through the unveiling of its own new GTC, allowing insourcing of its IT operations.
Faced with a series of R&D challenges and changes at the senior management level, AstraZeneca planned to invest in its new GTC at Chennai, which will significantly cut costs and will enable the company to fasten its grip on its work.
Though Bangalore is known to be the Silicon Valley of India, AstraZeneca sees Chennai as the perfect location for its primary GTC.
The company initially shortlisted a host of countries in Asia and Eastern Europe, but picked Chennai specifically to set its technology center in India.
"Chennai fits well with our strategy. The city is India's healthcare capital and along with leading hospitals and medical colleges, the city has a strong focus on the biotechnology industry sector. Equally important, Chennai is an emerging IT hotspot and there's a large population of IT talent here as well as in neighboring regions," said AstraZeneca's spokesperson to BioSpectrum.